SSS International Clinical Research

What SSS International Clinical Research does

Optimapharm (legal name Optimapharm d.o.o., associated in firmographic records with the name SSS International Clinical Research) is a private Contract Research Organization founded in 2007, headquartered in Zagreb, Croatia, with regional headquarters in Boston, Massachusetts (North America) and Chennai, India (Asia-Pacific). The company delivers integrated clinical research services to pharmaceutical, biotechnology, and medical device sponsors, with operational coverage across Europe, North America, and APAC. Its service model targets organizations requiring full-service clinical trial management, modular functional outsourcing, and real-world evidence generation, with a claimed 2x geographic reach across North America and Europe relative to the average mid-sized CRO and a track record of 86+ approved therapeutics delivered through partnered programs.

The product architecture is organized around three core service lines — Full Service Phase I-IV, Functional Service Provision (FSP), and Real World Research — augmented by five branded therapeutic platform suites: OptimaCardio Suite (cardiology), OptimaImmuno Suite (immunology), OptimaDerm Suite (dermatology), OptimaOnco Suite (oncology), and OptimaNeuro Suite (neurology). Each suite combines regulatory expertise, operational templates, and clinical know-how for the relevant therapeutic area, including support for novel in-house developed drugs at the sponsor level (a Phase 1b/2 colorectal cancer trial is cited in a CMO testimonial). The offering is professional-services in nature rather than a software or AI-driven platform; no proprietary technology, AI capabilities, APIs, or SDKs are disclosed.

The business model is B2B project-based contract revenue, with engagement terms shaped by study complexity, duration, patient enrollment targets, and geographic scope (no public pricing). Go-to-market runs through enterprise field sales with a proposal-based funnel, supplemented by LinkedIn presence, industry events, and a content-driven Resource Hub. The company does not disclose revenue, funding history, M&A activity, or detailed management team information; office footprint and therapeutic platform structure are the primary observable signals of scale.

Name

SSS International Clinical Research

Legal name

Optimapharm d.o.o.

Website

https://cro-sss.de

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

101–250 employees

Short description

Optimapharm is a private mid-sized CRO founded in 2007, headquartered in Zagreb, Croatia, providing Phase I-IV trial management, FSP, and real-world research services to pharmaceutical, biotechnology, and medical device sponsors across cardiology, immunology, dermatology, oncology, and neurology.

Ownership category

akta.pro rank

Product category

Contract Research Organization (CRO) Services

NAICS

Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Clinical CROs (Phase I–IV) (HLAGAAAA)

akta.pro secondary industries

Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL), Patient Recruitment, Site Feasibility & Trial Enablement CROs (HLAGAAAI)

Keywords

• Clinical research services
• Contract research organization
• Clinical trial management
• Functional service provision
• Real-world evidence

Headquarters

HQ city

Germering

HQ country

Germany

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

1. Clinical Research Services: Project-based contract revenue from providing full-service Phase I-IV clinical trial management, functional service provision (FSP), and real-world research services to pharmaceutical, biotech, and medical device companies.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

SSS International Clinical Research is a Contract Research Organization (CRO) providing comprehensive clinical trial management services for pharmaceutical, biotech, and medical device companies. Its portfolio includes Full Service Phase I-IV clinical trial management, Functional Service Provision (FSP) for flexible outsourcing, and Real World Research for evidence generation outside traditional trials, delivered through five specialized therapeutic platforms spanning Cardiology, Immunology, Dermatology, Oncology, and Neurology.

Product overview

Optimapharm is a Contract Research Organization (CRO) offering integrated clinical research services through a unified platform architecture. The core service portfolio consists of three primary offerings: Full Service Phase I-IV (comprehensive trial management), Functional Service Provision (FSP, flexible functional outsourcing), and Real World Research (real-world evidence generation). These core services are enhanced by five therapeutic platforms—OptimaCardioSuite, OptimaImmunoSuite, OptimaDermSuite, OptimaOncoSuite, and OptimaNeuroSuite—that provide specialized regulatory and operational expertise across cardiology, immunology, dermatology, oncology, and neurology therapeutic areas respectively. The company operates across North America, Europe, and APAC with global headquarters in Zagreb, Croatia.

Differentiator

Problem solved

Functional benefit

Brands

• OptimaCardio Suite: Cardiology therapeutic platform
• OptimaImmuno Suite
• OptimaDerm Suite
• OptimaOnco Suite
• OptimaNeuro Suite

Quantifiable outcome

• 86+ approved therapeutics delivered through partnered clinical programs

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Broad incumbents

• ICON plc: Global CRO offering full-service clinical research, FSP, and laboratory services. Comparable in Phase I-IV and FSP offerings but with materially deeper sponsor relationships and global infrastructure.
• IQVIA: Largest global CRO with comprehensive Phase I-IV, real-world evidence, and technology-enabled clinical services. Competes directly with Optimapharm on full-service trials but operates at vastly larger scale.
• Labcorp Drug Development (formerly Covance): Integrated CRO and central laboratory services provider. Comparable in central lab + clinical trial delivery, with significantly larger scale and broader geographic footprint.
• Charles River Laboratories: Provides preclinical and clinical research services including CRO offerings. Comparable in CRO function though its preclinical focus and scale differentiate it; competes on integrated drug development mandates.
• Syneos Health: Large biopharma solutions organization offering clinical and commercial services. Comparable on Phase I-IV clinical delivery and FSP/functional resourcing models, with much broader commercial reach.
• Parexel International: Large global CRO (now private post take-private) offering Phase I-IV, FSP, and real-world evidence. Overlaps Optimapharm's service portfolio and therapeutic breadth, though at much greater scale.

Direct peers

• Medpace Holdings: Mid-sized, therapeutically focused full-service CRO with global operations. Highly comparable in scale, therapeutic-area emphasis, and Phase I-IV delivery model to Optimapharm, though materially larger.
• PSI CRO: Privately held European-headquartered full-service CRO with global reach across the same therapeutic areas. Closely comparable in size, European origin, and full-service Phase I-IV delivery.
• Worldwide Clinical Trials: Mid-sized global CRO focused on Phase II-IV across multiple therapeutic areas. Comparable in service mix (full-service, FSP) and therapeutically-led operating model.
• Ergomed plc: Specialty CRO with strong oncology, rare disease, and pharmacovigilance focus. Comparable in therapeutic specialization and mid-size positioning, with similar FSP-style service offerings.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/sss-international-clinical-research

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SSS International Clinical Research